RED+BLUE STRATEGIES for PEW CHARITABLE TRUSTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA. H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - focused on reinvigorating the pipeline for new antibiotics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Medicare/Medicaid MMM
Implementation and rulemaking related to the Physician Payment Sunshine Act- a Medicare-related provision in the health reform law focused on systemic transparency. Discussions of including the new unique device identifiers in materials related to Medicare.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Health Issues HCR
Legislative issues that would allow incentives for the discovery and FDA approval of new antibiotics. Regulatory issues surrounding Unique Device Identifiers (UDI) being addressed by the Food and Drug Administration and Congressional oversight Regulatory issues regarding Meaningful Use 3 regulations being considered by CMS and congressional oversight.Implementation and rulemaking related to the Physician Payment Sunshine Act - A Medicare-related provision in the Health Reform Law focused on increasing systemic transparency. H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - ensuring that the pipeline for antibiotics is developed in the country.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.